Rinvoq Approved for UC; HCC Combo Flops; Disney Grants Pass to IBS Patient

The FDA approved upadacitinib (Rinvoq) to treat adults with moderately to severely active ulcerative colitis with an inadequate response or intolerance to at least one tumor necrosis factor (TNF) blocker, drugmaker AbbVie announced.

Non-invasive tests for liver fibrosis were less accurate among patients with type 2 diabetes. (Clinical Gastroenterology and Hepatology)

Cold snare resection was safe and effective for non-pedunculated colorectal lesions ranging 6-15 mm in size, a randomized trial found. (Gastrointestinal Endoscopy)

Exelixis said it will not seek approval of cabozantinib (Cabometyx) in combination with atezolizumab (Tecentriq) for untreated advanced hepatocellular carcinoma (HCC) after a phase III trial found no survival improvement over sorafenib (Nexavar).

A controversial TikTok video showed a woman bragging about how she received a “disability pass” for irritable bowel syndrome that allowed her to skip lines at Disney theme parks. (Newsweek)

COVID vaccination protected pancreatic transplant patients in Poland against serious complications of SARS-CoV-2 infection, despite being on immunosuppressive agents. (Transplantation Proceedings)

Within 6 months of each other, a young Denver couple were each diagnosed with stage IV colon cancer. (KUSA)

A new externally validated model predicted visible dysplastic recurrence after endoscopic eradication of Barrett’s esophagus for those with dysplasia or early cancer. (Gastroenterology)